Aerami Therapeutics is a clinical stage biopharmaceutical company dedicated to developing innovative inhaled therapies for the treatment of cardiopulmonary conditions. With a focus on precision inhaled drug delivery, Aerami leverages its proprietary inhalation technology to create differentiated products. Among their exciting pipeline are AER-901, a drug-device combination product candidate in Phase 1 for the treatment of pulmonary arterial hypertension, AER-601, an inhaled glucagon-like peptide-1 (GLP-1) analog for managing post-prandial hyperglycemia associated with Type 2 diabetes, and AER-501, a soft mist inhaled human insulin designed to improve glycemic control in both Type 1 and Type 2 diabetes patients.

With a commitment to improving the lives of individuals with cardiopulmonary diseases, Aerami Therapeutics aims to open new pathways for patients through innovative inhaled therapies. Stay informed about their advancements and progress by signing up for their email alerts